Graft-induced dyskinesias (GIDs), side-effects found in clinical grafting trials for Parkinson's disease (PD), may be associated with the withdrawal of immunosuppression. The goal of this study was to determine the role of the immune response in GIDs. We examined levodopa-induced dyskinesias (LIDs), GID-like behaviors, and synaptic ultrastructure in levodopa-treated, grafted, parkinsonian rats with mild (sham), moderate (allografts) or high (allografts plus peripheral spleen cell injections) immune activation. Grafts attenuated amphetamine-induced rotations and LIDs, but two abnormal motor syndromes (tapping stereotypy, litter retrieval/chewing) emerged and increased with escalating immune activation. Immunohistochemical analyses confirmed immune activation and graft survival. Ultrastructural analyses showed increases in tyrosine hydroxylase-positive (TH+) axo-dendritic synapses, TH+ asymmetric specializations, and non-TH+ perforated synapses in grafted, compared to intact, striata. These features were exacerbated in rats with the highest immune activation and correlated statistically with GID-like behaviors, suggesting that immunemediated aberrant synaptology may contribute to graft-induced aberrant behaviors.
Introduction
A major set-back to embryonic dopaminergic grafting trials in Parkinson's disease (PD) patients has been the development of troublesome post-graft abnormal involuntary movements in as many as 50% of trial participants (Hagell et al., 2002; Olanow et al., 2003) . These so-called graft-induced dyskinesias (GIDs) have characteristics largely unique from common levodopa-induced dyskinesias (LIDs) and appear to more closely resemble biphasic drug-induced dyskinesias (Cenci and Hagell, 2005) , often involving stereotypy and hyperkinesia and localized to either upper or lower extremities (Olanow et al., 2003; Hagell et al., 2002) . This is in contrast to peakdose LIDs, which are more widespread (involving both pair of extremities) and primarily dystonic and choreic (Fahn, 2000) . Unlike peak-dose LIDs, GIDs are most commonly noted when plasma levodopa levels are low. An animal model of GIDs has recently been reported (Steece-Collier et al., 2003; Maries et al., 2006; Lane et al., 2006; Carlsson et al., 2006) . While differences exist between clinical GIDs and the rat model, in both humans (Freed et al., 2001; Hagell et al., 2002; Olanow et al., 2003) and animals (Maries et al., 2006) , grafting embryonic dopaminergic neurons into the parkinsonian striatum can result in the development of novel, aberrant motor behaviors at extended post-graft intervals.
Clinical observations suggest a link between the host immune system and GIDs. Specifically, GIDs were reported in patients that received no immunosuppression (Freed et al., 2001) or soon after the withdrawal of immunosuppression (Olanow et al., 2003; Hagell and Cenci, 2005) . In two patients displaying GIDs, post-mortem examination showed that the surviving grafts were surrounded by activated microglia (Olanow et al., 2003) . This coincidence of GID development and immunosuppression withdrawal suggests that the host immune response contributes to the development of these behaviors following dopaminergic grafting in the parkinsonian brain; however, this hypothesis remains to be tested.
An immune-mediated alteration in synapses is a possible explanation for the emergence of GIDs (e.g.: Tonelli et al., 2005) . Indeed, synaptic remodeling is a key feature of neuroleptic-induced dyskinesias 
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